Search results
Found 1056 matches for
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.
Dan Perry
MBChB (Hons), MA(Oxon), PhD, FHEA, FRCS (Orth), FRCSEd (Ad Hominem) Dan Perry - Honorary Professor, Children's Orthopaedics & Trauma Surgery
David Beard
GDPhys, MCSP, MSc, MA, DPhil, FBOA (hon), FRCS (hon) David Beard - Professor of Musculoskeletal and Surgical Science
Vicki Barber
BSc (Hons) ; FIoB; PhD Vicki Barber - OCTRU Operations Director and Interim Joint CTU Director
Peter Taylor
MA, PhD, FRCP, FRCPE Peter Taylor - Norman Collisson Professor of Musculoskeletal Sciences
Jonathan Cook
BSc, PhD, CStat Jonathan Cook - Professor of Clinical Trials & Medical Statistics/OCTRU Deputy Director
Rebecca Brehm
MSc Clinical Trials, BSc (Hons) Biological Sciences Rebecca Brehm - Clinical Trial Administrator - Oncology Clinical Trials Office (OCTO)
